Patient demographics and disease characteristics at baseline
Characteristic . | All treated patients (n = 159), n (%) . |
---|---|
Age | |
Median, y (range) | 60 (33-71) |
≥65 y | 45 (28) |
Male | 106 (67) |
ECOG PS | |
0 | 110 (69) |
1 | 49 (31) |
Histology | |
CLL | 146 (92) |
SLL | 13 (8) |
Rai stage | |
0/I/II | 113 (71) |
III/IV | 44 (28) |
Missing | 2 (1) |
Bulky disease (cm) | |
≥5 | 48 (30) |
≥10 | 5 (3) |
Cytopenia at baseline | |
Any cytopenia | 54 (34) |
Hemoglobin ≤11 g/dL | 37 (23) |
Platelet count ≤100 × 109/L | 21 (13) |
ANC ≤1.5 × 109/L | 13 (8) |
Hierarchical cytogenetics (FISH) classification* | |
Del(17p) | 20 (13) |
Del(11q) | 28 (18) |
Trisomy 12 | 23 (14) |
Normal | 33 (21) |
Del(13q) | 54 (34) |
Unknown | 1 (1) |
Mutated TP53 | |
Yes | 16 (10) |
No | 142 (89) |
Unknown | 1 (1) |
Del(17p) or mutated TP53 | |
Yes | 27 (17) |
No | 129 (81) |
Unknown | 3 (2) |
IGHV gene mutation status | |
Unmutated | 89 (56) |
Mutated | 66 (42) |
Unknown | 4 (3) |
Complex karyotype† | |
Yes | 31 (19) |
No | 102 (64) |
Unknown | 26 (16) |
Characteristic . | All treated patients (n = 159), n (%) . |
---|---|
Age | |
Median, y (range) | 60 (33-71) |
≥65 y | 45 (28) |
Male | 106 (67) |
ECOG PS | |
0 | 110 (69) |
1 | 49 (31) |
Histology | |
CLL | 146 (92) |
SLL | 13 (8) |
Rai stage | |
0/I/II | 113 (71) |
III/IV | 44 (28) |
Missing | 2 (1) |
Bulky disease (cm) | |
≥5 | 48 (30) |
≥10 | 5 (3) |
Cytopenia at baseline | |
Any cytopenia | 54 (34) |
Hemoglobin ≤11 g/dL | 37 (23) |
Platelet count ≤100 × 109/L | 21 (13) |
ANC ≤1.5 × 109/L | 13 (8) |
Hierarchical cytogenetics (FISH) classification* | |
Del(17p) | 20 (13) |
Del(11q) | 28 (18) |
Trisomy 12 | 23 (14) |
Normal | 33 (21) |
Del(13q) | 54 (34) |
Unknown | 1 (1) |
Mutated TP53 | |
Yes | 16 (10) |
No | 142 (89) |
Unknown | 1 (1) |
Del(17p) or mutated TP53 | |
Yes | 27 (17) |
No | 129 (81) |
Unknown | 3 (2) |
IGHV gene mutation status | |
Unmutated | 89 (56) |
Mutated | 66 (42) |
Unknown | 4 (3) |
Complex karyotype† | |
Yes | 31 (19) |
No | 102 (64) |
Unknown | 26 (16) |